Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Launched by TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER, EL PASO · Mar 12, 2007
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
Intrinsic PEEP (Positive-End Expiratory Pressure) was measured by end-expiratory occlusion method and estimated using formulas derived from measured expiratory flows and a postulated linear pressure-flow relationship during expiration in passive ARDS patients. Agreement between measured and estimated intrinsic PEEP was analyzed by Bland and Altman's method.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years of age or older with diagnosis of ARDS, as defined by the American- European Consensus Conference 4
- • Receiving mechanical ventilation.
- • Presence of autoPEEP by inspection of flow-time waveforms displayed by the mechanical ventilator.
- Exclusion Criteria:
- • Known or suspected diagnosis of COPD or airflow limitation.
- • Next of kin not available to consent.
- • Contraindication to receive a muscle relaxant when measurements may be inaccurate without its administration.
- • Pregnancy
About Texas Tech University Health Sciences Center, El Paso
Texas Tech University Health Sciences Center, El Paso is a leading academic institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent sponsor of clinical trials, the center focuses on improving patient outcomes by rigorously investigating new therapies and treatment protocols across various medical disciplines. With a commitment to excellence and ethical standards, Texas Tech El Paso fosters collaboration among researchers, healthcare professionals, and community partners to address pressing health challenges and enhance the quality of care in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
El Paso, Texas, United States
Patients applied
Trial Officials
Juan Figueroa-Casas, MD
Principal Investigator
Texas Tech University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials